# Randomized, Placebo-crontrolled Clinical Trial Evaluating the Efficacy and Safety of Heparan Sulfate 120 mg Prolonged-Release Tablets Compared With Placebo in Patients With Chronic Venous Disease

> **NCT07684833** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Barbara Maglione** · enrollment: 174 (estimated)

## Conditions studied

- Chronic Venous Disease
- Vein Disease
- Venous Insufficiency of Leg

## Interventions

- **DRUG:** CLR Tablets - Heparan Sulphate
- **OTHER:** CLR Placebo

## Key facts

- **NCT ID:** NCT07684833
- **Lead sponsor:** Barbara Maglione
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-11
- **Primary completion:** 2027-05
- **Final completion:** 2027-05
- **Target enrollment:** 174 (ESTIMATED)
- **Last updated:** 2026-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07684833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07684833, "Randomized, Placebo-crontrolled Clinical Trial Evaluating the Efficacy and Safety of Heparan Sulfate 120 mg Prolonged-Release Tablets Compared With Placebo in Patients With Chronic Venous Disease". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07684833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*